궤양성 대장염 시장 : 약제 유형별, 질환 유형별, 지역별 경쟁, 산업 규모, 점유율, 동향, 기회 및 예측(2021-2031년)
Ulcerative Colitis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Disease Type, By Region & Competition. 2021-2031F
상품코드:1901732
리서치사:TechSci Research
발행일:2026년 01월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 궤양성 대장염 시장은 2025년 80억 6,000만 달러에서 2031년까지 113억 6,000만 달러에 달하고, CAGR 5.89%로 성장할 것으로 예측됩니다.
궤양성 대장염은 대장과 직장의 지속적인 염증과 점막 궤양을 특징으로 하는 만성 염증성 장질환으로, 아미노살리실산 제제, 코르티코스테로이드, 첨단 생물학적 제제를 포함한 약물 요법에 대한 지속적인 수요를 창출하고 있습니다.
시장 개요
예측기간
2027-2031년
시장 규모(2025년)
80억 6,000만 달러
시장 규모(2031년)
113억 6,000만 달러
CAGR(2026-2031년)
5.89%
최대 성장 부문
궤양성 직장염
최대 시장
북미
주요 촉진요인
신규 생물학적 제제 및 저분자 치료제의 신속한 승인은 전통적인 치료에 거부감이 있는 환자의 임상 요구에 직접 대응하고 시장 확대의 주요 추진력이 되고 있습니다. 규제 당국은 인터루킨-23 억제제와 야누스 키나아제 억제제 등 다양한 작용기전을 가진 약물을 점차 승인하고 있으며 따라서 소화기 전문의가 이용할 수 있는 치료 옵션이 다양화되고 있습니다.
주요 시장 과제
신규 생물학적 제형 및 저분자 치료제의 높은 가격은 세계의 궤양성 대장염 시장 성장에 심각한 제약 요인이 되고 있습니다. 이러한 첨단 치료는 임상적 관해를 초래하며, 많은 비용으로 인해 공공 및 민간 보험 지불자는 처방약 단계화나 엄격한 사전 승인 요건 등 강화된 비용 억제책 실시를 요구받고 있습니다.
주요 시장 동향
주요 생물학적 제형에 대한 비용 효과적인 바이오시밀러의 보급은 기존 블록버스터 제품의 독점성을 해소함으로써 세계의 궤양성 대장염 시장을 근본적으로 재구성하고 있습니다. 우스테키누맙 및 아달리무맙과 같은 주력요법의 특허보호가 해제되는 가운데 고품질 바이오시밀러의 적극적인 진입이 가격 경쟁을 촉진하고 여태까지 막대한 비용으로 인해 제한된 생물학적 제제치료에 대한 환자 접근을 확대하고 있습니다.
The Global Ulcerative Colitis Market will grow from USD 8.06 Billion in 2025 to USD 11.36 Billion by 2031 at a 5.89% CAGR. Ulcerative colitis is a chronic inflammatory bowel disease characterized by continuous inflammation and mucosal ulceration in the colon and rectum, creating a sustained demand for pharmacotherapies including aminosalicylates, corticosteroids, and advanced biologics.
Market Overview
Forecast Period
2027-2031
Market Size 2025
USD 8.06 Billion
Market Size 2031
USD 11.36 Billion
CAGR 2026-2031
5.89%
Fastest Growing Segment
Ulcerative Proctitis
Largest Market
North America
Key Market Drivers
The accelerated approval of novel biologics and small molecule therapies serves as a primary catalyst for market expansion, directly addressing the clinical needs of patients refractory to conventional treatments. Regulatory agencies are increasingly authorizing agents with distinct mechanisms of action, such as interleukin-23 inhibitors and Janus kinase inhibitors, which diversifies the therapeutic arsenal available to gastroenterologists. This regulatory momentum ensures a steady influx of advanced treatment options that offer improved remission rates and safety profiles, encouraging healthcare providers to switch patients from older protocols to newer, more effective regimens.
Key Market Challenges
The prohibitive pricing of novel biologic and small molecule therapies constitutes a severe restraint on the growth of the global ulcerative colitis market. Although these advanced treatments provide necessary clinical remission, their substantial costs compel public and private payers to implement stringent cost-containment measures, such as tiered formulary placement and rigorous prior authorization requirements. These financial barriers frequently force physicians to reserve high-efficacy drugs for only the most severe cases, effectively capping the sales volume of premium products and slowing revenue generation across the sector.
Key Market Trends
The proliferation of cost-effective biosimilars for major biologics is fundamentally reshaping the global ulcerative colitis market by dismantling the exclusivity of incumbent blockbusters. As patent protections for flagship therapies like ustekinumab and adalimumab expire, the aggressive entry of high-quality biosimilars is driving price competition and expanding patient access to biologic treatments previously restricted by prohibitive costs.
Key Market Players
Johnson and Johnson
Allergan, Inc.
Merck & Co., Inc.
Novartis AG
Bausch Health Companies Inc.
AstraZeneca Plc
Eli Lilly & Company
Pfizer Inc.
Sanofi SA
GlaxoSmithKline Plc.
Report Scope:
In this report, the Global Ulcerative Colitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Ulcerative Colitis Market, By Drug Type:
Anti-Inflammatory Drugs
Anti-TNF biologics
Immuno-suppressants
Calcineurin Inhibitors
and Other
Ulcerative Colitis Market, By Disease Type:
Ulcerative Proctitis
Proctosigmoiditis
Left-sided Colitis
Pancolitis or Universal Colitis
and Fulminant Colitis
Ulcerative Colitis Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Ulcerative Colitis Market.
Available Customizations:
Global Ulcerative Colitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Ulcerative Colitis Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Type (Anti-Inflammatory Drugs, Anti-TNF biologics, Immuno-suppressants, Calcineurin Inhibitors, and Other)
5.2.2. By Disease Type (Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. North America Ulcerative Colitis Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Type
6.2.2. By Disease Type
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Ulcerative Colitis Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Type
6.3.1.2.2. By Disease Type
6.3.2. Canada Ulcerative Colitis Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Type
6.3.2.2.2. By Disease Type
6.3.3. Mexico Ulcerative Colitis Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Type
6.3.3.2.2. By Disease Type
7. Europe Ulcerative Colitis Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type
7.2.2. By Disease Type
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Ulcerative Colitis Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Disease Type
7.3.2. France Ulcerative Colitis Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Disease Type
7.3.3. United Kingdom Ulcerative Colitis Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Disease Type
7.3.4. Italy Ulcerative Colitis Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Type
7.3.4.2.2. By Disease Type
7.3.5. Spain Ulcerative Colitis Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Type
7.3.5.2.2. By Disease Type
8. Asia Pacific Ulcerative Colitis Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type
8.2.2. By Disease Type
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Ulcerative Colitis Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Disease Type
8.3.2. India Ulcerative Colitis Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Disease Type
8.3.3. Japan Ulcerative Colitis Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Disease Type
8.3.4. South Korea Ulcerative Colitis Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Type
8.3.4.2.2. By Disease Type
8.3.5. Australia Ulcerative Colitis Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Type
8.3.5.2.2. By Disease Type
9. Middle East & Africa Ulcerative Colitis Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type
9.2.2. By Disease Type
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Ulcerative Colitis Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Disease Type
9.3.2. UAE Ulcerative Colitis Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Disease Type
9.3.3. South Africa Ulcerative Colitis Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Disease Type
10. South America Ulcerative Colitis Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Type
10.2.2. By Disease Type
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Ulcerative Colitis Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Disease Type
10.3.2. Colombia Ulcerative Colitis Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Disease Type
10.3.3. Argentina Ulcerative Colitis Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Type
10.3.3.2.2. By Disease Type
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Ulcerative Colitis Market: SWOT Analysis
